title: HBV reactivation in an occult HBV infection patient treated with prednisone for nephrotic syndrome: case report and literature review.
abstract: BACKGROUND
  Reactivation of hepatitis B virus (HBV), characterized by increased levels of serum HBV DNA, abnormal liver function and hepatic failure, is a frequent complication of immunosuppressive therapy and chemotherapy in patients with HBV infection. However, reactivation of occult HBV infection with immunosuppressive therapy or chemotherapy is rare.
  
  
  METHODS
  A 77-year-old man was diagnosed with nephrotic syndrome and IgM nephropathy with unclear pathogenesis. Liver function was normal, HBV-related serum markers were negative and HBV DNA titer was below the upper limits of normal. Two months following the start of prednisone therapy for his nephrotic syndrome, laboratory tests revealed a substantial increase in serum transaminase levels (ALT: 490 IU/L; AST: 149 IU/L) and an elevation of HBV DNA level (3.42×10(6) copies/ml). We tested stored kidney tissue for HBsAg and HBcAg using immunohistochemistry and found the sample to be HBcAg positive, allowing us to confirm the etiology of nephropathy as an occult HBV infection. The cause of the hepatitis was thought to be HBV reactivation, so we immediately administered lamivudine. One month after the initiation of daily lamivudine treatment, laboratory tests revealed that serum levels of transaminases had improved (ALT: 35 IU/L; AST: 17 IU/L). Patient examination one year later showed that HBeAg had decreased with a concomitant increase of HBeAb, the quantity of HBV DNA was undetectable, and liver function and renal function had stabilized.
  
  
  CONCLUSIONS
  This is the first report describing HBV reactivation in an occult HBV infection patient treated with oral prednisone for nephrotic syndrome. HBV-associated antigen should be regularly tested for in patients with unknown etiological glomerulonephritis in areas with high HBV viral popular and even in those with no clinical evidence for diagnosis of HBV.
authors: Department of Liver Disease, Jinan Infectious Disease Hospital, Shandong University School of Medicine, Jinan 250021, China.
authors: Wenjun
authors: W
authors: Du
authors: Zhaomin
authors: Z
authors: Zheng
authors: Shaolei
authors: S
authors: Han
authors: Shumin
authors: S
authors: Ma
authors: Shijun
authors: S
authors: Chen
mesh_terms: D000368:Aged; D004279:DNA, Viral / Q000097:blood; D006509:Hepatitis B / Q000821:virology*; D006801:Humans; D007678:Kidney Glomerulus / Q000473:pathology; D008297:Male; D009404:Nephrotic Syndrome / Q000188:drug therapy* / Q000821:virology*; D011241:Prednisone / Q000008:administration & dosage* / Q000009:adverse effects; D012008:Recurrence
chemical_list: D004279:DNA, Viral; D011241:Prednisone
references: Am J Gastroenterol. 1997 Jan;92(1):3-17
references: 8995930
references: J Hepatol. 2007 Jan;46(1):160-70
references: 17112622
references: Pediatr Nephrol. 1996 Feb;10(1):76-8
references: 8611364
references: N Engl J Med. 1991 Jun 13;324(24):1705-9
references: 2034247
references: Medicine (Baltimore). 1990 Jul;69(4):200-16
references: 2142748
references: Lancet. 1974 Aug 31;2(7879):477-82
references: 4136754
references: J Med Virol. 1999 May;58(1):1-10
references: 10223539
references: Ann Intern Med. 2008 Apr 1;148(7):519-28
references: 18378948
references: Clin Nephrol. 1988 May;29(5):229-34
references: 3293854
references: Kidney Int. 1995 Jan;47(1):225-30
references: 7731150
references: J Med Virol. 2004 Aug;73(4):508-15
references: 15221893
references: Arch Pathol. 1974 Apr;97(4):193-200
references: 4273591
references: Arch Dis Child. 1983 Jul;58(7):488-96
references: 6870328
references: Hepatology. 2004 Oct;40(4):865-73
references: 15382123